ERAS

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 36,142,857 shares of its common stock, including 4,714,285 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $17.50 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other off

8-K - Erasca, Inc. (0001761918) (Filer)

424B5 - Erasca, Inc. (0001761918) (Filer)

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 31,428,572 shares of its common stock. The shares of common stock are being sold to the public at a price of $17.50 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $

424B5 - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. In addition, Erasca intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock. There can be no assurance a

S-3ASR - Erasca, Inc. (0001761918) (Filer)

At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated at RDEs Promising combination potential, including no DLTs, encouraging safety data, and clearance of first dose escalation combination cohort of ERAS-0015 (16 mg) with approved commercial dose of panitumumab Additional ERAS-0015 monotherapy and combination data expected H1 2027, including panitumumab combination data Company plans to initiate a potentially registration-enabling trial in lung cancer in H1 2027, a Phase 3 trial in pancreatic cancer in 2027, and an additional Phase 3 tri

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

BofA Securities upgraded Erasca from Underperform to Neutral and set a new price target of $16.00

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcas

SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)

SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)

SCHEDULE 13G - Erasca, Inc. (0001761918) (Subject)

SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)

10-Q - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS-0015 monotherapy expansion and combination dose escalation data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $409 million as of March 31, 2026 expected to fund operations into H2 2028 SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, an

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Merck, known as MSD outside of the United States and Canada. This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of patients with RAS-mutant (RASm) solid tumors. Erasca is sponsoring the study, and Merck is supplyi